Intangible Assets Activity (Detail) - USD ($) |
Aug. 31, 2020 |
May 31, 2020 |
Aug. 31, 2019 |
|---|---|---|---|
| Acquired Finite-Lived Intangible Assets [Line Items] | |||
| Leronlimab (PRO 140) patent | $ 3,500,000 | $ 3,500,000 | $ 3,500,000 |
| Website development costs | 20,000 | 20,000 | |
| Accumulated amortization | (5,687,000) | (5,190,000) | |
| Total amortizable intangible assets, net | 12,959,000 | 13,456,000 | |
| Patents currently not amortized | 0 | 0 | |
| Carrying value of intangibles, net | 12,959,000 | 13,456,000 | |
| ProstaGene, LLC | |||
| Acquired Finite-Lived Intangible Assets [Line Items] | |||
| ProstaGene, LLC intangible asset acquisition | $ 15,126,000 | $ 15,126,000 |
| X | ||||||||||
- Definition Finite-lived intangible assets, website development costs incurred. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|